Physician profile
Anthony A Lee
NPI 1184689416
$4,093.70
in general payments reported to CMS, 2019-2025
20 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $338 · 2021: $303 · 2022: $554 · 2023: $603 · 2024: $880 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,240.05 | 2022-2025 | |
| Abbott Laboratories | $613.46 | 2020-2025 | Proclaim, Eterna |
| Allergan, INC. | $575.30 | 2019-2022 | |
| Bioventus LLC | $384.55 | 2020-2025 | Xcell, Gelsyn-3, Durolane |
| Lundbeck LLC | $360.17 | 2024-2025 | Vyepti |
| Daiichi Sankyo INC. | $175.45 | 2019 | |
| Smith+Nephew, INC. | $131.40 | 2020 | |
| Boston Scientific Corporation | $125.85 | 2020 | |
| Fidia Pharma USA INC. | $94.68 | 2022-2024 | Hymovis |
| Ferring Pharmaceuticals INC. | $80.69 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $57.45 | 2024 | Dysport |
| Nevro Corp. | $53.79 | 2019-2022 | |
| Depuy Synthes Sales INC. | $46.94 | 2022-2023 | Orthovisc |
| Pacira Therapeutics, INC. | $27.93 | 2019 | |
| Collegium Pharmaceutical, INC. | $27.64 | 2023 | Xtampza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $25.58 | 2021-2023 | Intellis Adaptivestim |
| Kci USA, INC. | $20.00 | 2022 | |
| Avanos Medical | $19.34 | 2023 | Trivisc Sodium Hyaluronate |
| Kowa Pharmaceuticals America, INC. | $17.84 | 2023 | Seglentis |
| Horizon Therapeutics Plc | $15.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.